GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
D

Dongsung Pharmaceutical Co 002210.KS · KRW

Health Care · KRX · 🇰🇷 South Korea

Compare

1,119

+2.29%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩87.17bn

FY2016FY2025

Net income

−₩25.74bn

FY2016FY2025

Free cash flow

−₩14.20bn

FY2016FY2025

Shareholders' equity

₩23.37bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue₩87.17bn₩88.45bn₩88.59bn₩93.33bn₩84.41bn₩87.80bn₩86.54bn₩91.91bn₩82.39bn₩79.72bn
Gross profit₩37.11bn₩38.76bn₩41.44bn₩42.06bn₩33.54bn₩34.15bn₩33.08bn₩35.19bn₩36.10bn₩37.10bn
Research and development₩3.73bn₩4.52bn₩4.17bn₩4.12bn₩3.40bn₩3.37bn₩3.10bn₩3.00bn₩2.46bn₩2.35bn
Operating income−₩12.69bn−₩5.73bn₩665.1m−₩3.10bn−₩5.30bn−₩3.67bn−₩5.25bn−₩5.03bn₩955.1m−₩2.29bn
Net income−₩25.74bn−₩14.57bn−₩5.97bn−₩2.12bn−₩4.31bn−₩14.08bn−₩8.39bn−₩5.74bn−₩198.3m−₩1.66bn
Diluted earnings per share-1,090.52-617.42-252.79-89.90-182.74-596.56-355.30-243.41-8.40-70.36

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets₩168.44bn₩140.67bn₩111.00bn₩107.70bn₩104.58bn₩125.72bn₩131.73bn₩140.20bn₩124.18bn₩125.39bn
Total liabilities₩145.07bn₩96.70bn₩75.09bn₩64.89bn₩58.14bn₩70.77bn₩61.63bn₩82.71bn₩59.91bn₩69.77bn
Debt—₩614.0m₩18.52bn₩7.73bn₩9.59bn₩12.33bn₩27.65bn₩42.65bn₩31.22bn₩40.07bn
Shareholders' equity₩23.37bn₩43.97bn₩35.91bn₩42.81bn₩46.44bn₩54.95bn₩70.10bn₩57.48bn₩64.27bn₩55.62bn
Shares outstanding24m24m24m24m24m24m24m24m24m24m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−₩12.86bn−₩14.84bn−₩6.29bn−₩3.88bn−₩2.75bn₩5.01bn−₩8.31bn₩1.39bn₩1.80bn−₩3.34bn
Capital spending−₩1.34bn−₩2.47bn−₩923.6m−₩642.9m−₩2.32bn−₩6.92bn−₩1.42bn−₩2.13bn−₩3.00bn−₩2.84bn
Free cash flow−₩14.20bn−₩17.30bn−₩7.22bn−₩4.53bn−₩5.08bn−₩1.91bn−₩9.73bn−₩733.5m−₩1.21bn−₩6.19bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₩22.08bn₩19.12bn₩19.06bn₩21.80bn₩19.96bn₩26.34bn₩22.56bn₩21.44bn
Gross profit₩8.35bn₩9.08bn₩7.15bn₩9.97bn₩7.43bn₩12.55bn₩9.46bn₩9.72bn
Operating income−₩4.39bn₩1.13bn−₩7.07bn₩411.1m−₩4.15bn₩742.9m—−₩698.1m
Net income−₩5.89bn₩14.0m−₩5.75bn₩112.3m−₩18.79bn−₩1.31bn−₩4.57bn−₩1.46bn
Diluted earnings per share-249.750.59-243.834.76-796.08-55.37-193.57-61.92
Cash from operations−₩19.54bn−₩138.0m−₩3.31bn−₩2.27bn₩4.20bn−₩11.48bn₩3.01bn−₩2.12bn
Capital spending−₩498.0m−₩131.0m−₩115.0m−₩206.0m—−₩1.31bn−₩1.62bn−₩116.0m
Free cash flow−₩20.04bn−₩269.0m−₩3.42bn−₩2.48bn—−₩12.79bn₩1.39bn−₩2.24bn
Total assets₩159.77bn₩288.50bn₩168.44bn₩145.92bn₩147.95bn₩168.60bn₩151.91bn₩121.76bn
Debt———₩325.0m₩400.0m₩507.0m₩614.0m₩721.0m
Shareholders' equity₩87.49bn₩93.38bn₩23.37bn₩40.66bn₩40.55bn₩55.93bn₩55.18bn₩37.09bn

Financial ratios

Data as of 23 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Gross margin42.6%43.8%46.8%45.1%39.7%38.9%—
Operating margin-14.6%-6.5%0.8%-3.3%-6.3%-4.2%—
Net margin-29.5%-16.5%-6.7%-2.3%-5.1%-16.0%—
Return on equity-110.1%-33.1%-16.6%-5.0%-9.3%-25.6%—
Return on assets-15.3%-10.4%-5.4%-2.0%-4.1%-11.2%—
Free cash flow yield——————-23.1%
Revenue growth-1.4%-0.2%-5.1%10.6%-3.9%1.5%—
Earnings growth76.6%144.2%181.2%-50.8%-69.4%67.9%—
Current ratio0.69x0.74x1.27x1.14x1.33x1.49x—
Debt to equity—0.01x0.52x0.18x0.21x0.22x0.39x
Equity ratio13.9%31.3%32.4%39.7%44.4%43.7%—
Interest coverage-1.30x-1.53x0.30x-2.37x-7.44x-4.32x—
R&D as a share of sales4.3%5.1%4.7%4.4%4.0%3.8%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-2.3%-0.1%1.6%
Operating income60.0%28.2%—
Net income129.8%12.8%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin43.2%44.6%42.9%42.9%
Operating margin-10.5%-5.8%-5.6%-4.3%
Net margin-23.0%-13.5%-12.6%-8.7%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-0.9-2.6-8.0-26.0-16.1-7.3-15.8-21.5-206.2-20.8
Price to sales0.30.40.50.60.81.21.51.30.50.4

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 27 Dec 2013.

FY2014FY2013FY2012FY2011FY2010FY2009FY2008FY2007
Paid in the year30.0030.0030.0030.0030.006.0030.0040.00
  • 5-for-1 split · 2 Jan 2009
  • 1.03-for-1 split · 4 Jan 1999
  • 1.03-for-1 split · 3 Jan 1998
  • 11-for-10 split · 25 Mar 1997
  • 1.02-for-1 split · 3 Jan 1996
  • 1.025-for-1 split · 3 Jan 1995

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.